Authors’ checklist non-clinical trial – Below you will find a checklist to help you prepare your manuscript to meet the guidelines for revision. Once the checklist is complete, and revisions have been incorporated—please acknowledge in the cover letter that the checklist has been completed, and please clearly indicate (page numbers) where in the manuscript any changes have been made. Please note, that if the paper is accepted, we cannot proceed to Production until the journal guidelines have been met. General points Please clearly indicate funding and non-financial support and the role of funders at end of □ Discussion section. We cannot allow priority claims, such as Please rephrase any instances □ “first”, “new”, “novel”. in the text. Define all abbreviations. □ Please give actual numbers (numerator and denominator) together with percentages. □ All abstracts and references press” should be updated with DOIs or page numbers as □ “in appropriate. For papers listed in references that are press” we need to see a galley proof “in and/or letter from the publisher stating that it is press” as well as (where known) the full “in expected citation (i.e., publication date/volume/issue etc.). References that are “submitted” should be removed and citations in the text replaced with data; authors)”. “(unpublished Avoid slashes (except ratios). □ Compound structures for all compounds used in the manuscript must be provided, per journal □ policy. Please either refer to published chemical structure, or provide complete geometric representation of the molecular structure in the manuscript, if referring to a new compound. Use approved gene names. Italicize (approved gene names only) and format appropriately □ (e.g., all caps for human genes, first letter cap for mouse genes see – http://www.genenames.org/ or ). Please use American English throughout. □ Reporting standards
Authors’ checklist – non-clinical trial Below you will find a checklist to help you prepare your manuscript to meet the guidelines for revision. Once the checklist is complete, and revisions have been incorporated—please acknowledge in the cover letter that the checklist has been completed, and please clearly indicate (page numbers) where in the manuscript any changes have been made. Please note, that if the paper is accepted, we cannot proceed to Production until the journal guidelines have been met. General points □ Please clearly indicate funding and non-financial support and the role of funders at end of Discussion section. □ We cannot allow priority claims, such as “first”, “new”, “novel”. Please rephrase any instances in the text. □ Define all abbreviations. □ Please give actual numbers (numerator and denominator) together with percentages. □ All abstracts and references “in press” should be updated with DOIs or page numbers as appropriate. For papers listed in references that are “in press” we need to see a galley proof and/or letter from the publisher stating that it is “in press” as well as (where known) the full expected citation (i.e., publication date/volume/issue etc.). References that are “submitted” should be removed and citations in the text replaced with “(unpublished data; authors)”. □ Avoid slashes (except ratios). □ Compound structures for all compounds used in the manuscript must be provided, per journal policy. Please either refer to published chemical structure, or provide complete geometric representation of the molecular structure in the manuscript, if referring to a new compound. □ Use approved gene names. Italicize (approved gene names only) and format appropriately (e.g., all caps for human genes, first letter cap for mouse genes – see http://www.genenames.org/ or ). □ Please use American English throughout. Reporting standards